Developer docs
API playgroundTry for free, no card

Search company profiles

Geropharm

Full company profile

uuid000fozv

Namestring
Geropharm
Legal namestring
OOO GEROPHARM (GEROPHARM LTD)
Websiteurl
geropharm.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Geropharm is a Russian pharmaceutical and biotechnology company founded in 2001 and headquartered in Saint Petersburg. It holds the #1 position in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers. The company employs over 1,600 people and operates across Russia and 14 foreign countries, with a therapeutic focus on endocrinology (insulin and metabolic disease as the core franchise), neurology and psychiatry, ophthalmology, and gynecology. Customers are served through B2B pharmaceutical distribution, including Russian state procurement, pharmacy networks, and government-backed export partnerships.

The technological backbone is full-cycle recombinant DNA biotechnology using proprietary E. coli strains for insulin production, an architecture that makes Russia the fifth country globally with end-to-end gene-engineering insulin manufacturing capability. Manufacturing is anchored at two sites: Obolensk in the Moscow Region, covering approximately 30% of Russian insulin demand, and Pushkin in Saint Petersburg, designed at full capacity to cover 100% of Russian insulin needs. The portfolio spans original medicines, biosimilar recombinant human insulins and insulin analogues, generics, and combination products, supported by a 35-product pipeline that includes Rinsulin, RinFast, RinGlar, Rinformin Long, Evodin (a proprietary DPP-4 inhibitor, evogliptin), and Semavik (semaglutide produced under compulsory license). Four granted patents protect the core insulin-producing strain.

The revenue model is product sales of prescription pharmaceuticals via Russian pharmacy distribution and via authorised distributors and government partnerships in export markets (Uzbekistan, Azerbaijan, Myanmar, and China). Commercial channels include field medical representatives targeting healthcare professionals, physician training programmes with health ministries (notably Uzbekistan since 2022), and government-level engagement at international forums such as SPIEF. In 2025 the company has accelerated international expansion through two flagship moves: the launch of a Russia-China Industrial Biomedicine and Pharmaceutics Institute in Guangzhou with FEFU and Chinese partners, and an insulin localisation partnership with R-Pharm in Azerbaijan.

Short descriptiontext

Geropharm is the #1 insulin manufacturer in Russia and a top-10 global producer. The Russian biotech company operates full-cycle gene-engineering insulin manufacturing and serves diabetes, neurology, ophthalmology, and gynecology markets across Russia and 14 export countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSaint Petersburg, Russia
HQ citystring
Saint Petersburg
HQ countrystring
Russia
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, insulin production, biotechnology products, biosimilar medicines, recombinant DNA technology
Industry5 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAHAE
Insulin Pen Needles, Syringes & Infusion Sets (Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Insulin Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Products Sales
TypeOne Time License
Description

Sale of proprietary and biosimilar pharmaceutical products across endocrinology, neurology, psychiatry, ophthalmology, and gynecology therapeutic areas. Pipeline includes 35 products including original medicines, biosimilar recombinant human insulins and insulin analogues, and generics.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Geropharm is a Russian biotechnological pharmaceutical manufacturer that develops and produces a portfolio of 35 products including proprietary and biosimilar recombinant human insulins, insulin analogues, oral antidiabetics, neurological, ophthalmological, and gynecological medications. The company operates full-cycle gene-engineering insulin manufacturing from active pharmaceutical ingredient synthesis through finished dosage form at its Obolensk and Pushkin facilities in Russia. It is the #1 player in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Rinsulin substance ahead of international standards in degree of purification from impurities
+2 more records
Product overview1 text field

GEROPHARM is an international rapidly growing biotechnological company and the leader in the Russian insulin market, ranked among the TOP-10 global insulin manufacturers. The company operates a portfolio of 35 products spanning original medicines, biosimilar recombinant human insulins, insulin analogues, and generics. Core offerings include multiple insulin formulations covering all therapeutic segments: short-acting insulins (Rinsulin® R, RinFast®), intermediate-acting (Rinsulin® NPH), premixed combinations (Rinsulin® Mix 30/70, RinFast® Mix 30, RinLis® Mix 25), and long-acting analogues (RinGlar®, Insulin Degludec in development). Oral antidiabetics include Rinformin® Long (metformin ER) and Evodin® (DPP-4 inhibitor), alongside obesity treatment Semavik® (semaglutide) and pipeline therapy Sejaro® (tirzepatide). Neurological portfolio features original products Cortexin® and its pediatric formulation, Recognan®, Levetinol®, and Memantinol® for CNS conditions. Ophthalmological offerings center on Retinalamin®, the only Russian retinoprotective agent. Gynecological product Pineamin® addresses menopausal syndrome. The company maintains full-cycle manufacturing capabilities producing from substance synthesis through finished dosage forms, with Rinsapen® II reusable pen-injector providing drug delivery for its insulin cartridge products.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-26
Description

Strategic partnership for localisation of insulin production in Azerbaijan. Agreement provides for localisation of secondary packaging processes for three insulin products (RinGlar, RinFast, RinFast Mix) at R-Pharm facilities in Baku. First production campaign completed and products entered commercial market. R-Pharm facility covers 4.6 hectares with state-of-the-art technology producing over 250 million units annually.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-16
Description

Launched first International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou, China. Institute provides platform for educational programmes in biomedicine and healthcare; trains professionals for high-tech manufacturing. Studies start September 2025 at Xinhua University campuses. Plans for mirror biomedicine laboratories at FEFU and Xinhua University.

3Guangzhou Xinhua University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-16
Description

Partner in International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou. Host institution for joint educational programmes in biomedicine and healthcare starting September 2025 at campuses in Guangzhou and Dongguan.

4Guangzhou Trauer Biotechnology Co.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-16
Description

Co-founder of International Industrial Biomedicine and Pharmaceutics Institute alongside GEROPHARM, FEFU, and Xinhua University. Represents Chinese business component of the joint institute structure.

5Guangzhou Pharmaceuticals
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2025-05-16
Description

One of the leading pharmaceutical corporations in Guangzhou supporting the Russia-China Industrial Biomedicine Institute. Partnership offers internships at modern facilities and jobs to alumni; supports commercialisation of scientific research.

6Ministry of Health of Uzbekistan
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Supported diabetes prevention, diagnosis, and management initiatives. In 2022, initiated physician training programme at endocrinology centres to prepare trainers for diabetes schools in all regions of Uzbekistan. GEROPHARM has been exporting products to Uzbekistan since 2021 with five insulin products approved.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in diabetes care and insulin manufacturing, originator of major insulin analogues and Ozempic (semaglutide). Directly comparable as a full-cycle insulin and GLP-1 producer with which Geropharm competes in technology and product categories.

TypeBroad incumbent
Description

Global pharmaceutical company with a major diabetes franchise (Lantus, Toujeo, insulins) and broader cardiometabolic portfolio. Comparable to Geropharm as a multinational insulin and cardiometabolic drug manufacturer.

TypeBroad incumbent
Description

Major global insulin manufacturer (Humalog, Humulin, Basaglar) and originator of Mounjaro (tirzepatide). Comparable as a producer of insulin analogues and next-generation incretin therapies overlapping with Geropharm's pipeline.

TypeDirect peer
Description

Indian biopharmaceutical company focused on biosimilar insulins and affordable diabetes care for emerging markets. Closely comparable to Geropharm as a biosimilar insulin manufacturer serving cost-sensitive markets with a similar export-oriented model.

TypeDirect peer
Description

Largest Russian pharmaceutical manufacturer with broad branded and generic portfolio across multiple therapeutic areas. Comparable as a domestic Russian pharma peer competing in the same state procurement channels and therapeutic segments as Geropharm.

TypeDirect peer
Description

Russian biotechnology company developing biosimilars, generics, and original biologics. Comparable as a domestic biotech peer in biosimilar development and Russian state-aligned biopharma production.

TypeDirect peer
Description

Russian biopharmaceutical manufacturer specializing in biosimilars, gene therapy, and blood products. Comparable as a domestic full-cycle biotech manufacturer competing for Russian state procurement and biosimilar market share.

TypeRegional player
Description

Major Russian pharmaceutical manufacturer and Geropharm's localization partner in Azerbaijan for insulin secondary packaging. Comparable as a domestic Russian pharma peer and the operational partner for Geropharm's CIS export model.

9Gulf Pharmaceutical Industries (Julphar)
TypeRegional player
Description

MENA-region pharmaceutical manufacturer producing insulins, biosimilars, and generics primarily for the Middle East and Africa. Comparable to Geropharm as a regional full-cycle insulin and biopharma producer with an export-led growth model.

10Polysan
TypeRegional player
Description

Russian pharmaceutical manufacturer with branded products in neurology, psychiatry, and endocrinology (including Cytoflavin). Comparable to Geropharm as a domestic Russian pharma peer overlapping in neurology, cardiology, and metabolic therapy areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Geropharm

Insulin Pharmaceuticalsgeropharm.com

Geropharm is the #1 insulin manufacturer in Russia and a top-10 global producer. The Russian biotech company operates full-cycle gene-engineering insulin manufacturing and serves diabetes, neurology, ophthalmology, and gynecology markets across Russia and 14 export countries.

What Geropharm does

Geropharm is a Russian pharmaceutical and biotechnology company founded in 2001 and headquartered in Saint Petersburg. It holds the #1 position in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers. The company employs over 1,600 people and operates across Russia and 14 foreign countries, with a therapeutic focus on endocrinology (insulin and metabolic disease as the core franchise), neurology and psychiatry, ophthalmology, and gynecology. Customers are served through B2B pharmaceutical distribution, including Russian state procurement, pharmacy networks, and government-backed export partnerships.

The technological backbone is full-cycle recombinant DNA biotechnology using proprietary E. coli strains for insulin production, an architecture that makes Russia the fifth country globally with end-to-end gene-engineering insulin manufacturing capability. Manufacturing is anchored at two sites: Obolensk in the Moscow Region, covering approximately 30% of Russian insulin demand, and Pushkin in Saint Petersburg, designed at full capacity to cover 100% of Russian insulin needs. The portfolio spans original medicines, biosimilar recombinant human insulins and insulin analogues, generics, and combination products, supported by a 35-product pipeline that includes Rinsulin, RinFast, RinGlar, Rinformin Long, Evodin (a proprietary DPP-4 inhibitor, evogliptin), and Semavik (semaglutide produced under compulsory license). Four granted patents protect the core insulin-producing strain.

The revenue model is product sales of prescription pharmaceuticals via Russian pharmacy distribution and via authorised distributors and government partnerships in export markets (Uzbekistan, Azerbaijan, Myanmar, and China). Commercial channels include field medical representatives targeting healthcare professionals, physician training programmes with health ministries (notably Uzbekistan since 2022), and government-level engagement at international forums such as SPIEF. In 2025 the company has accelerated international expansion through two flagship moves: the launch of a Russia-China Industrial Biomedicine and Pharmaceutics Institute in Guangzhou with FEFU and Chinese partners, and an insulin localisation partnership with R-Pharm in Azerbaijan.

Geropharm firmographics

Firmographics
Name
Geropharm
Legal name
OOO GEROPHARM (GEROPHARM LTD)
Website
https://geropharm.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
Geropharm is the #1 insulin manufacturer in Russia and a top-10 global producer. The Russian biotech company operates full-cycle gene-engineering insulin manufacturing and serves diabetes, neurology, ophthalmology, and gynecology markets across Russia and 14 export countries.
Ownership category
akta.pro rank

Geropharm industry classification

Industry
Product category
Insulin Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAHAHAE
Insulin Pen Needles, Syringes & Infusion Sets (Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

Keywords

  • Pharmaceutical manufacturing
  • Insulin production
  • Biotechnology products
  • Biosimilar medicines
  • Recombinant DNA technology

Where Geropharm is headquartered

Location

Headquarters

HQ city
Saint Petersburg
HQ country
Russia
HQ region
Europe

Offices4 records

Markets served

Geropharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Products Sales: Sale of proprietary and biosimilar pharmaceutical products across endocrinology, neurology, psychiatry, ophthalmology, and gynecology therapeutic areas. Pipeline includes 35 products including original medicines, biosimilar recombinant human insulins and insulin analogues, and generics.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Geropharm product offering

Product offering

Core offering

Geropharm is a Russian biotechnological pharmaceutical manufacturer that develops and produces a portfolio of 35 products including proprietary and biosimilar recombinant human insulins, insulin analogues, oral antidiabetics, neurological, ophthalmological, and gynecological medications. The company operates full-cycle gene-engineering insulin manufacturing from active pharmaceutical ingredient synthesis through finished dosage form at its Obolensk and Pushkin facilities in Russia. It is the #1 player in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers.

Product overview

GEROPHARM is an international rapidly growing biotechnological company and the leader in the Russian insulin market, ranked among the TOP-10 global insulin manufacturers. The company operates a portfolio of 35 products spanning original medicines, biosimilar recombinant human insulins, insulin analogues, and generics. Core offerings include multiple insulin formulations covering all therapeutic segments: short-acting insulins (Rinsulin® R, RinFast®), intermediate-acting (Rinsulin® NPH), premixed combinations (Rinsulin® Mix 30/70, RinFast® Mix 30, RinLis® Mix 25), and long-acting analogues (RinGlar®, Insulin Degludec in development). Oral antidiabetics include Rinformin® Long (metformin ER) and Evodin® (DPP-4 inhibitor), alongside obesity treatment Semavik® (semaglutide) and pipeline therapy Sejaro® (tirzepatide). Neurological portfolio features original products Cortexin® and its pediatric formulation, Recognan®, Levetinol®, and Memantinol® for CNS conditions. Ophthalmological offerings center on Retinalamin®, the only Russian retinoprotective agent. Gynecological product Pineamin® addresses menopausal syndrome. The company maintains full-cycle manufacturing capabilities producing from substance synthesis through finished dosage forms, with Rinsapen® II reusable pen-injector providing drug delivery for its insulin cartridge products.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Rinsulin substance ahead of international standards in degree of purification from impurities
  • +2 more outcomes

Companies that use Geropharm

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Geropharm technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

Feature3 records

Geropharm partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • R-Pharm AzerbaijancoreStrategic or Co-development Partner · 26 May 2025Strategic partnership for localisation of insulin production in Azerbaijan. Agreement provides for localisation of secondary packaging processes for three insulin products (RinGlar, RinFast, RinFast Mix) at R-Pharm facilities in Baku. First production campaign completed and products entered commercial market. R-Pharm facility covers 4.6 hectares with state-of-the-art technology producing over 250 million units annually.
  • Far Eastern Federal University (FEFU)coreStrategic or Co-development Partner · 16 May 2025Launched first International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou, China. Institute provides platform for educational programmes in biomedicine and healthcare; trains professionals for high-tech manufacturing. Studies start September 2025 at Xinhua University campuses. Plans for mirror biomedicine laboratories at FEFU and Xinhua University.
  • Guangzhou Xinhua UniversitycoreStrategic or Co-development Partner · 16 May 2025Partner in International Industrial Biomedicine and Pharmaceutics Institute in Guangzhou. Host institution for joint educational programmes in biomedicine and healthcare starting September 2025 at campuses in Guangzhou and Dongguan.
  • Guangzhou Trauer Biotechnology Co.coreStrategic or Co-development Partner · 16 May 2025Co-founder of International Industrial Biomedicine and Pharmaceutics Institute alongside GEROPHARM, FEFU, and Xinhua University. Represents Chinese business component of the joint institute structure.
  • Guangzhou PharmaceuticalsminorGTM or Marketing Partner · 16 May 2025One of the leading pharmaceutical corporations in Guangzhou supporting the Russia-China Industrial Biomedicine Institute. Partnership offers internships at modern facilities and jobs to alumni; supports commercialisation of scientific research.
  • Ministry of Health of UzbekistancoreStrategic or Co-development Partner · 1 January 2022Supported diabetes prevention, diagnosis, and management initiatives. In 2022, initiated physician training programme at endocrinology centres to prepare trainers for diabetes schools in all regions of Uzbekistan. GEROPHARM has been exporting products to Uzbekistan since 2021 with five insulin products approved.

Scale indicators9 records

Recent moves8 records

Expansion highlights7 records

Geropharm competitors and assessment

Company assessment

Broad incumbents

  • Novo Nordisk: Global leader in diabetes care and insulin manufacturing, originator of major insulin analogues and Ozempic (semaglutide). Directly comparable as a full-cycle insulin and GLP-1 producer with which Geropharm competes in technology and product categories.
  • Sanofi: Global pharmaceutical company with a major diabetes franchise (Lantus, Toujeo, insulins) and broader cardiometabolic portfolio. Comparable to Geropharm as a multinational insulin and cardiometabolic drug manufacturer.
  • Eli Lilly: Major global insulin manufacturer (Humalog, Humulin, Basaglar) and originator of Mounjaro (tirzepatide). Comparable as a producer of insulin analogues and next-generation incretin therapies overlapping with Geropharm's pipeline.

Direct peers

  • Biocon: Indian biopharmaceutical company focused on biosimilar insulins and affordable diabetes care for emerging markets. Closely comparable to Geropharm as a biosimilar insulin manufacturer serving cost-sensitive markets with a similar export-oriented model.
  • Pharmstandard: Largest Russian pharmaceutical manufacturer with broad branded and generic portfolio across multiple therapeutic areas. Comparable as a domestic Russian pharma peer competing in the same state procurement channels and therapeutic segments as Geropharm.
  • BIOCAD: Russian biotechnology company developing biosimilars, generics, and original biologics. Comparable as a domestic biotech peer in biosimilar development and Russian state-aligned biopharma production.
  • Generium: Russian biopharmaceutical manufacturer specializing in biosimilars, gene therapy, and blood products. Comparable as a domestic full-cycle biotech manufacturer competing for Russian state procurement and biosimilar market share.

Regional players

  • R-Pharm: Major Russian pharmaceutical manufacturer and Geropharm's localization partner in Azerbaijan for insulin secondary packaging. Comparable as a domestic Russian pharma peer and the operational partner for Geropharm's CIS export model.
  • Gulf Pharmaceutical Industries (Julphar): MENA-region pharmaceutical manufacturer producing insulins, biosimilars, and generics primarily for the Middle East and Africa. Comparable to Geropharm as a regional full-cycle insulin and biopharma producer with an export-led growth model.
  • Polysan: Russian pharmaceutical manufacturer with branded products in neurology, psychiatry, and endocrinology (including Cytoflavin). Comparable to Geropharm as a domestic Russian pharma peer overlapping in neurology, cardiology, and metabolic therapy areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Geropharm social profiles

Digital presence

Geropharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Geropharm leadership team

Management profile

Number of profiles

Geropharm funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Geropharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Geropharm

What does Geropharm do?

Geropharm is a Russian biotechnological pharmaceutical manufacturer that develops and produces a portfolio of 35 products including proprietary and biosimilar recombinant human insulins, insulin analogues, oral antidiabetics, neurological, ophthalmological, and gynecological medications. The company operates full-cycle gene-engineering insulin manufacturing from active pharmaceutical ingredient synthesis through finished dosage form at its Obolensk and Pushkin facilities in Russia. It is the #1 player in the Russian insulin market and ranks among the TOP-10 global insulin manufacturers.

Is Geropharm a public or private company?

Geropharm is a private company. It is classified as unknown and is currently operating.

When was Geropharm founded?

Geropharm was founded in 2001. It employs 101 to 250 people.

Where is Geropharm based?

Geropharm is headquartered in Saint Petersburg, Russia, in the Europe region.

How does Geropharm make money?

One revenue line is on record: pharmaceutical Products Sales.

Who are Geropharm's main competitors?

Broad incumbents on record are Novo Nordisk, Sanofi and Eli Lilly. Direct peers are Biocon, Pharmstandard, BIOCAD and Generium. Regional players are R-Pharm, Gulf Pharmaceutical Industries (Julphar) and Polysan.

Does Geropharm have an API?

No public API is recorded for Geropharm.

What industry is Geropharm in?

Geropharm's product category is Insulin Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterRussia’s Geropharm is seeking legal action to use five Novo Nordisk patentsRussian drugmaker Geropharm is seeking legal action to use five Novo Nordisk patents related to semaglutide, including an oral dosage form and cardiovascular use. The company demands a licensing agreement granting a simple, non-exclusive license.UzdailyВ Узбекистане зарегистрирован первый тирзепатид Sejaro® от ГЕРОФАРМ для терапии ожирения и сахарного диабета 2 типаHERO PHARM received a registration certificate for Sejaro (tirzepatide) for obesity and type 2 diabetes in Uzbekistan. The drug is bioequivalent to Eli Lilly's Mounjaro, and 64% of adults have excess weight. The company plans to expand access to the therapy.UzdailyGEROPHARM Receives Halal Certification for Diabetes DrugsGEROPHARM received halal certification for its diabetes and obesity drugs Sejaro, Semavic, and Semavic Next from the International Halal Standardization and Certification Center. The certification confirms compliance with Islamic requirements, including the absence of prohibited substances. The company expects the certification to enable doctors and patients to use modern therapies while respecting religious considerations.DrugPatentWatchRussia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration DataThis article is a strategic analytical guide explaining how Russia's VED (828 INNs) and SSM (215 drugs) pharmaceutical reimbursement lists function under different procurement rules, with particular focus on the 'Second Extra' mechanism (Resolution No. 1875) that automatically excludes non-full-cycle EAEU producers from VED state tenders when a qualifying domestic bid is present. The article uses the semaglutide compulsory licensing case (where Geropharm and Promomed received government authorization to produce Novo Nordisk's Ozempic without consent under Article 1360) as a primary example of how patent holders from 'unfriendly countries' face elevated compulsory licensing risk when supply is withdrawn from VED/SSM-listed molecules. Russia has set a 2030 target of 90% domestic production for VED-listed drugs, making EAEU full-cycle API localization the essential qualification for state procurement access, while the commercial pharmacy segment (1.85 trillion roubles in 2025) operates under different rules where Second Extra does not apply.DrugPatentWatchRussia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right NowRussia's pharmaceutical patent-term extension (PTE) mechanism under Article 1363 of the Civil Code provides up to five years of extended exclusivity through supplementary patents with claims narrowed to the authorized product, but compulsory licenses under Article 1360 can override these protections entirely for companies from 'unfriendly countries,' with compensation currently set at 0% of generic manufacturer revenue. Major Western pharmaceutical companies including Gilead, Novo Nordisk, and Vertex have had their Russian and Eurasian patents compulsorily licensed since 2022, with domestic manufacturers Geropharm, Promomed, and Pharmasintez producing generic versions of drugs including Ozempic (semaglutide), Veklury (remdesivir), and Trikafta without meaningful compensation to the originators. The Pharma 2030 strategy targets 90% domestic production of essential medicines by 2030, creating a policy environment where foreign patents on vital and essential drugs are effectively targets for compulsory licensing, with Chinese companies now surpassing U.S. filers as the top foreign patent applicants in Russia's $9.2 billion pharmaceutical market.DrugPatentWatchBeyond the Third Wheel Rule: How Patent Filings Predict Russia’s API and Full-Cycle Drug Production PushRussia is undergoing a fundamental shift in its pharmaceutical procurement policy, replacing the binary Third Wheel rule with a granular points-based system effective January 2026 that makes full-cycle API synthesis mathematically necessary for state procurement access, eliminating secondary packaging as a sufficient compliance strategy. Patent filings at Rospatent serve as the earliest signals of domestic API synthesis intent, with domestic companies filing process patents, polymorph patents, and challenging originator patents 18-36 months before capital investment materializes. The semaglutide compulsory license established the operational template: Novo Nordisk's exit from Russia triggered government-authorized production at 0.5% royalty, allowing Geropharm, Promomed, and PSK Pharma to capture nearly 100% of the domestic market within 12 months and begin exporting within two years.GeneOnline NewsThe 2026 GLP-1 Patent Cliff: Generics, Global Competition, and the $100 Billion M&A RaceThe pharmaceutical industry is entering its first GLP-1 patent cliff as liraglutide, the active ingredient in Novo Nordisk's Victoza and Saxenda, becomes the first widely available generic GLP-1 drug following FDA approvals for Teva, Cipla, and Biocon in 2025-2026, with analysts forecasting price reductions of up to 70% in price-sensitive markets. While semaglutide (Ozempic, Wegovy) remains protected in the United States and Europe until 2031-2032, patents are expiring in China, India, Brazil, and Canada beginning in 2026, with Brazil additionally denying patent extension requests and Russia utilizing compulsory licensing to allow domestic manufacturers GEROPHARM, PROMO-MED, and PSK Pharma to produce semaglutide analogues at significantly lower prices. Industry analysts project the resulting market restructuring will drive over $100 billion in M&A activity and create a two-tier GLP-1 economy separating high-volume generic therapies from premium-priced next-generation treatments like retatrutide.GlobeNewswireUnited States Rapid Acting Insulin Research Report 2025: A $3.4 Billion Market by 2033 Featuring Adocia, Biocon, Eli Lilly, Gan & Lee, Geropharm, MannKind, Merck, Novo Nordisk, Sanofi, WockhardtResearchAndMarkets.com released a market report projecting the United States rapid-acting insulin market will grow from $2.32 billion in 2024 to $3.40 billion by 2033, representing a compound annual growth rate of 4.33%. Key growth drivers include rising diabetes prevalence, advancements in insulin delivery technologies such as pens and closed-loop pumps, and increasing demand for personalized diabetes management solutions. The report identifies cost challenges and patient adherence as market restraints, while listing Eli Lilly, Novo Nordisk, and Sanofi among the major players operating in this space.The Pharma LetterPharmaceutical Generics Industry NewsNovo Nordisk is attempting to halt exports of a Russian generic version of Ozempic (semaglutide) produced by Geropharm, according to reports. Concurrently, Granules India’s US subsidiary received tentative FDA approval for a generic amphetamine tablet for ADHD, with a 180-day exclusivity period.